Promising new MMRC clinical trials enrolling relapsed and refractory patients now
Empliciti™ / Pomalyst ® / Dex A study of Empliciti ( elotuzumab ) in combination with Pomalyst ( pomalidomide ) and low dose dexamethasone ( dex ) is open for multiple myeloma patients who have relapsed after or are refractory to a prior treatment with a Revlimid ® ( lenalidomide ) based regimen . This is an interventional Phase II , multi-center , open-label , single arm study to assess the safety and efficacy of this combination therapy . Based on patient response , this therapy could potentially serve as a possible second or third line treatment regimen after Revlimid stops working .
Empliciti™ / Pomalyst ® / Velcade ® / Dex A study of Empliciti ( elotuzumab ) in combination with Pomalyst ( pomalidomide ), Velcade ( bortezomib ) and dexamethasone is open for patients who have received at least two prior therapies and are relapsed and / or refractory to both lenalidomide and bortezomib . This is an interventional Phase II , multi-center , open-label , single arm study to assess the safety and efficacy , and evaluate the objective response rate ( partial response or better ), of elotuzumab in combination with pomalidomide , bortezomib , and dexamethasone .
Ninlaro ® and Dex vs . Ninlaro ® , Dex and Revlimid ® ; Randomized with NFKB2 Rearrangement This interventional , randomized , Phase II , single-center trial is for patients with multiple myeloma that has returned after a period of improvement or who do not respond to treatment . It studies how well Ninlaro ( ixazomib citrate ) and dexamethasone or Ninlaro , dexamethasone and Revlimid ( lenalidomide ) work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 ( NFKB2 ) in treating .
Questions about clinical trials ? Please call our MMRF Nurse Specialists at 1-800-603-6628 . To search for clinical trials visit myelomatrials . org
Clinical Trials Currently Open for Enrollment |
Key |
Novel Agents Mechanisms
PIs and IMIDs
|
Antibodies and Immune
Molecularly Targeted
|
Phase I Phase I / II
Phase II
|
SAR 650984 / Kyprolis |
CB-5083 |
Mdm2i / Ixa 17p deleted |
PINR / Ninlaro / Revlimid / Dex |
SAR 650984 |
Relapsed or R / R |
PDL-1 /
Revlimid ( Same trial )
|
ABT 199 |
Ibrutinib / Kyprolis |
Empliciti / Pomalyst / Dex |
Empliciti / Velcade Pomalyst / Dex |
|
Pomalyst / Dex / Kyprolis |
Marizomib / Pomalyst |
|
Pomalyst / Ninlaro |
|
New Dx ./ Transplant
PDL-1 / Revlimid ( Same trial ) ( Post-Transplant )
Ninlaro / Revlimid / Dex Transplant WU = Washington University • UC = University of Chicago
SMM
Darzalex Empliciti / Dex / Revlimid
10 THEMMRF . ORG
Promising new MMRC clinical trials
enrolling relapsed and refractory patients now
Empliciti™/Pomalyst®/Dex
Empliciti™/Pomalyst®/Velcade®/Dex
Ninlaro® and Dex vs. Ninlaro®, Dex
A study of Empliciti (elotuzumab)
A study of Empliciti (elotuzumab)
and Revlimid®; Randomized with
in combination with Pomalyst
in combination with Pomalyst
NFKB2 Rearrangement
(pomalidomide) and low dose
(pomalidomide), Velcade (bortezomib)
This interventional, randomized,
dexamethasone (dex) is open for
and dexamethasone is open for patients
Phase II, single-center trial is for
multiple myeloma patients who have
who have received at least two prior
patients with multiple myeloma that has
relapsed after or are refractory to
therapies and are relapsed and/or
returned after a period of improvement
a prior treatment with a Revlimid
refractory to both lenalidomide and
or who do not respond to treatment.
(lenalidomide) based regimen. This is
bortezomib. This is an interventional
It studies how well Ninlaro (ixazomib
an interventional Phase II, multi-center,
Phase II, multi-center, open-label,
citrate) and dexamethasone or
open-label, single arm study to assess the
single arm study to assess the safety
Ninlaro, dexamethasone and Revlimid
safety and efficacy of this combination
and efficacy, and evaluate the objective
(lenalidomide) work based on the
therapy. Based on patient response,
response rate (partial response or
presence of the rearrangement of a
this therapy could potentially serve as a
better), of elotuzumab in combination
gene called nuclear factor of kappa
possible second or third line treatment
with pomalidomide, bortezomib, and
light polypeptide gene enhancer in
regimen after Revlimid stops working.
dexamethasone.
B-cells 2 (NFKB2) in treating.
®
Questions about clinical trials? Please call our MMRF Nurse Specialists at 1-800-603-6628.
To search for clinical trials visit myelomatrials.org
Key
Clinical Trials Currently
Open for Enrollment
Phase I
Relapsed
or R/R
New Dx./
Transplant
SMM
10
Novel Agents Mechanisms
Antibodies and Immune
PIs and IMIDs
Molecularly Targeted
Phase I/II
Phase II
SAR 650984/
Kyprolis
CB-5083
Mdm2i/Ixa
17p deleted ��S��Ӛ[�\���]�[ZY�^���T�
�LN
��LK�]�[ZY
�[YH�X[
B��P�NNB��X��][�X��\��\�[\X�]K�X[\��^��[\X�]Kՙ[�YB��X[\��^���X[\�^��\��\�X\�^��ZX��X[\���LKԙ]�[ZY
�[YH�X[
B���U�[��[�
B���X[\��[�\���[�\��ԙ]�[ZY�^�[��[���HH�\�[��ۈ[�]�\��]H8�(�P�H[�]�\��]Hو�X�Y��\��[^��[\X�]K�^�]�[ZY�HST���ԑ�